期刊
BRITISH JOURNAL OF CANCER
卷 102, 期 1, 页码 173-180出版社
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6605462
关键词
prognostic; REMARK; survival analysis; tumour marker; reporting guideline
类别
资金
- Cancer Research UK
- BMG (Federal Ministry of Health)
BACKGROUND: Poor reporting compromises the reliability and clinical value of prognostic tumour marker studies. We review articles to assess the reporting of patients and events using REMARK guidelines, at the time of guideline publication. METHODS: We sampled 50 prognostic tumour marker studies from higher impact cancer journals between 2006 and 2007. The inclusion criteria were cancer; focus on single biological tumour marker; survival analysis; multivariable analysis; and not gene array or proteomic data. Articles were assessed for the REMARK profile and other REMARK guideline items. We propose a reporting aid, the REMARK profile, motivated by the CONSORT flowchart. RESULTS: In 50 studies assessed for the REMARK profile, the number of eligible patients (56% of articles), excluded patients (54%) and patients in analyses (98%) was reported. Only 50% of articles reported the number of outcome events. In multivariable analyses, 54% and 30% of articles reported patient and event numbers for all variables. Of the studies, 66% used archival samples, indicating a potentially biased patient selection. Only 36% of studies reported clearly defined outcomes. CONCLUSIONS: Good reporting is critical for the interpretability and clinical applicability of prognostic studies. Current reporting of key information, such as the number of outcome events in all patients and subgroups, is poor. Use of the REMARK profile would greatly improve reporting and enhance prognostic research. British Journal of Cancer (2010) 102, 173-180. doi:10.1038/sj.bjc.6605462 www.bjcancer.com Published online 8 December 2009 (C) 2010 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据